Evidence map›Paper›PMID 41799333›Full record

ArticleThe Journal of innovations in cardiac rhythm management2026

Heart Rate Threshold Settings for Ventricular Tachycardia in Patients with Wearable Cardioverter-defibrillators.

Steve Ringquist, Nicole R Bianco, Patricia Tung

Abstract read
In one paragraph

Article in The Journal of innovations in cardiac rhythm management, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Steve RingquistZOLL CMS, Pittsburgh, PA, USA.
Nicole R BiancoZOLL CMS, Pittsburgh, PA, USA.
Patricia TungBeth Israel Deaconess Medical Center, Boston, MA, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The wearable cardioverter-defibrillator (WCD) uses programmable heart rate (HR) and detection time to determine the need for shock delivery, but the optimal ventricular tachycardia (VT) HR detection zone is unknown. The LifeVest™ (ZOLL Medical, Chelmsford, MA, USA) WCD has a default VT detection rate of 150 bpm. We found that 15% of appropriate shocks among WCD recipients were delivered for VT 150-170 bpm and that 30% of these patients experienced loss of consciousness. Based on these findings, a programmed VT detection threshold of 150 bpm should be considered.

Indexed as

Cardiac defibrillatorcardiovertventricular tachycardiawearable cardioverter-defibrillator

Identifiers

PMID41799333
PMCPMC12962278

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.